Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Visible and near-infrared hyperspectral imaging techniques allow the reliable quantification of prognostic markers in lymphomas: A pilot study using the Ki67 proliferation index as an example.
Willenbacher E, Brunner A, Willenbacher W, Zelger B, Wolf D, Rogge D, Tappert M, Pallua JD. Willenbacher E, et al. Among authors: wolf d. Exp Hematol. 2020 Nov;91:55-64. doi: 10.1016/j.exphem.2020.09.191. Epub 2020 Sep 20. Exp Hematol. 2020. PMID: 32966868 Free article.
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R. Them NC, et al. Among authors: wolf d. Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25545244 Free PMC article. Clinical Trial.
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Gisslinger H, et al. Among authors: wolf d. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10. Blood. 2015. PMID: 26261238 Free PMC article. Clinical Trial.
Curcumin: New Insights into an Ancient Ingredient against Cancer.
Willenbacher E, Khan SZ, Mujica SCA, Trapani D, Hussain S, Wolf D, Willenbacher W, Spizzo G, Seeber A. Willenbacher E, et al. Among authors: wolf d. Int J Mol Sci. 2019 Apr 12;20(8):1808. doi: 10.3390/ijms20081808. Int J Mol Sci. 2019. PMID: 31013694 Free PMC article. Review.
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.
Mondello P, Musolino C, Dogliotti I, Bohn JP, Cavallo F, Ferrero S, Botto B, Cerchione C, Nappi D, De Lorenzo S, Martinelli G, Wolf D, Schmitt C, Loseto G, Cuzzocrea S, Willenbacher W, Mian M, Straus DJ. Mondello P, et al. Among authors: wolf d. Am J Hematol. 2020 Sep;95(9):1030-1037. doi: 10.1002/ajh.25871. Epub 2020 Jun 30. Am J Hematol. 2020. PMID: 32419224 Free article. Clinical Trial.
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event.
Locher M, Steurer M, Jukic E, Keller MA, Fresser F, Ruepp C, Wöll E, Verdorfer I, Gastl G, Willenbacher W, Weger R, Nachbaur D, Wolf D, Gunsilius E, Zschocke J, Steiner N. Locher M, et al. Among authors: wolf d. Am J Hematol. 2020 Dec;95(12):1562-1571. doi: 10.1002/ajh.25994. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32936982 Free PMC article. Clinical Trial.
2,848 results